报告题目：药物研发系列讲座Ⅵ——Post-Artemisinin anti-malaria drug discovery

报  告  人：Dr. Tao Wu（Wellspring Biosciences）

时        间：2015年10月15日 下午15:00

地        点：重庆大学创新药物研究中心学术报告厅

报告人简历：

Dr. Tao Wu is currently a senior scientist and chemistry project leader at Wellspring Biosciences, where he focuses on the discovery and development of small molecule drugs that target signal transduction networks for the treatment of cancer and other diseases. Between 2010 and 2013, Dr. Wu was a staff scientist at Life Technologies developing biology reagents especially novel carriers of nucleic acid-based biologics for in vitro and in vivo applications. Between 2006 and 2010, he was an Institute Fellow at Genomics Institute of the Novartis Research Foundation (GNF) working on anti-malarial drug discovery. He was a key member of a small team that discovered the phase II clinical candidate KAF156. Prior to coming to the States in 2001, he had worked in Shanghai Institute of Organic Chemistry studying radical cyclization reactions. Dr. Wu is a senior VP, board director and chair of China Connection Committee of Sino-American Biomedical & Pharmaceutical Professionals Association (SABPA). Dr. Wu obtained a M.S. degree from Dalian University of Technology. He received his Ph.D. degree in organic chemistry from Iowa State University in 2006.